Last reviewed · How we verify

NALBUPHINE HYDROCHLORIDE — Competitive Intelligence Brief

NALBUPHINE HYDROCHLORIDE (NALBUPHINE HYDROCHLORIDE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed kappa opioid receptors, mu opioid receptors Small molecule Live · refreshed every 30 min

Target snapshot

NALBUPHINE HYDROCHLORIDE (NALBUPHINE HYDROCHLORIDE). Nalbuphine activates kappa opioid receptors and blocks mu opioid receptors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NALBUPHINE HYDROCHLORIDE TARGET NALBUPHINE HYDROCHLORIDE marketed kappa opioid receptors, mu opioid receptors 1979-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NALBUPHINE HYDROCHLORIDE — Competitive Intelligence Brief. https://druglandscape.com/ci/nalbuphine-hydrochloride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: